Your new post is loading...
Abstract
The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.
Via Krishan Maggon
Lisa H Butterfield16*, Mary L Disis2, Bernard A Fox3, Samir N Khleif4 and Francesco M Marincola5
*Corresponding author: Lisa H Butterfield butterfieldl@upmc.edu
Author Affiliations
1University of Pittsburgh, Pittsburgh, PA, USA
2University of Washington, Seattle, WA, USA
3Oregon Health and Science University, Portland, OR, USA
4GRU Cancer Center, Georgia Regents University, Augusta, GA, USA
5Sidra Medical and Research Center, Doha, Qatar
6University of Pittsburgh, Hillman Cancer Center, 5117 Centre Avenue, Suite 1.27, Pittsburgh 15213, PA, USA
For all author emails, please log on.
Journal for Immunotherapy of Cancer 2015, 3:8 doi:10.1186/s40425-015-0052-6
The electronic version of this article is the complete one and can be found online at:http://www.immunotherapyofcancer.org/content/3/1/8